Results 31 to 40 of about 3,909 (222)

Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome [PDF]

Clinical and Molecular Hepatology, 2013
Terlipressin is a vasopressin analogue that is widely used in the treatment of hepatorenal syndrome or variceal bleeding. Because it acts mainly on splanchnic vessels, terlipressin has a lower incidence of severe ischemic complications than does ...
Hae Rim Kim, Young Sun Lee, Hyung Joon Yim, Hyun Joo Lee, Ja Young Ryu, Hyun Jung Lee, Eileen L. Yoon, Sun Jae Lee, Jong Jin Hyun, Sung Woo Jung, Ja Seol Koo, Rok Sun Choung, Sang Woo Lee, Jai Hyun Choi   +13 more
doaj   +1 more source

INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion

Contemporary Clinical Trials Communications, 2023
Background: Hepatorenal syndrome-acute kidney injury (HRS-AKI) carries significant morbidity and mortality among those with end-stage liver disease. Bolus terlipressin for treatment of HRS-AKI received FDA approval in September 2022. US implementation of
Ethan Weinberg, Suditi Rahematpura, Stevan A. Gonzalez, Manhal J. Izzy, Douglas A. Simonetto, R. Todd Frederick, Raymond A. Rubin, Jade Ikahihifo-Bender, Maggie Harte, Grace Kim-Lee, Sherry Witkiewicz, William Tobin, Khurram Jamil, Zachary Fricker, K. Rajender Reddy   +14 more
doaj   +1 more source

Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites

GastroHep, 2022
Background. Terlipressin is a long acting synthetic analogue of vasopressin, which is used to manage variceal bleeding and hepatorenal syndrome.
Jasmohan S. Bajaj, James H. Fischer, Patrick Yeramian, Edith A. Gavis, Andrew Fagan, Paolo Angeli, Guadalupe Garcia-Tsao, Jonathan M. Adams, Penelope Markham   +8 more
doaj   +1 more source

Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile

Gastroenterology Insights, 2023
Hepatorenal syndrome stands as one of several potential triggers of acute kidney injury in individuals grappling with either acute or persistent liver ailments. The nature of the decline in kidney function has led to the identification of two variants of
Ahlam Ayyad, Rami A. Al-Horani
doaj   +1 more source

Two-component vasopressor therapy for septic shock

Вестник анестезиологии и реаниматологии, 2021
The objective: to investigate the efficacy and safety of terlipressin when it is used as an additional vasopressor in septic shock.Subjects: A single-center, observational, retrospective-prospective study of the efficacy and safety of combined therapy of
A. A. Kochkin, V. V. Likhvantsev, К. К. Kadantseva   +2 more
doaj   +1 more source

Antiparallel β‐Sheet as a Key Motif of Amyloid‐β Inhibitor Designed via Topological Peptide Reprogramming

Angewandte Chemie, Volume 137, Issue 28, July 7, 2025.
Targeting Amyloid‐β (Aβ) aggregation requires a peptide‐based approach that accounts for the structural heterogeneity of Aβ. Here, we employ topological reprogramming via disulfide bonds to stabilize antiparallel β‐sheets within the dimeric peptide.
Dongjoon Im, Ye Eun Lee, Gyusub Yoon, William A. Goddard III, Tae Su Choi, Hugh I. Kim   +5 more
wiley   +2 more sources

Vasoconstrictor Therapy for Acute Kidney Injury Hepatorenal Syndrome: A Meta-Analysis of Randomized Studies

Gastro Hep Advances, 2023
Background and Aims: Type 1 hepatorenal syndrome (HRS) is a rapid deterioration in kidney function in patients with cirrhosis. Data on efficacy of vasoconstrictors for type 1 HRS have shown mixed results.
Ashwani K. Singal, Geralyn Palmer, Lauren Melick, Mohamed Abdallah, Paul Kwo   +4 more
doaj   +1 more source

The current applications and future directions of terlipressin. [PDF]

Hepatol Commun
Terlipressin is a vasopressin analog with potent splanchnic vasoconstrictor properties. It has an established role in managing portal hypertensive bleeding and hepatorenal syndrome-acute kidney injury, with a growing body of evidence demonstrating improved safety and efficacy with continuous infusion-based administration compared to bolus dosing.
Liu D, Testro A, Majumdar A, Sinclair M.
europepmc   +3 more sources

Is there any role for terlipressin in the extremely low birth weight infant with refractory septic shock?

Journal of Pediatric and Neonatal Individualized Medicine, 2012
Terlipressin, a synthetic long-acting analogue of vasopressin, has been investigated as a second line vasopressor in adults and children with refractory septic shock, i.e.
Francesca Bissolo, Carlo Alberto Forcellini, Stefania Spaggiari, Marcella Gaffuri, Giuseppe Pagano, Paolo Biban   +5 more
doaj   +1 more source

Continuous terlipressin infusion is associated with improved diet intake and muscle strength in patients awaiting liver transplant

JHEP Reports, 2019
Background & Aims: Portal hypertension contributes to the pathogenesis of malnutrition and sarcopenia in cirrhosis via multiple mechanisms. Terlipressin is a vasopressin analogue that we administer via continuous outpatient infusion, as a bridge to ...
Brooke Chapman, Paul Gow, Marie Sinclair, Timothy Hanrahan, Peter Angus, Tess McClure, Chris Mills, Ryma Terbah, Adam Testro   +8 more
doaj   +1 more source